Cargando…

Autoimmune Diabetes Associated With Pembrolizumab: A Review of Published Case Reports

The utility of immunotherapy, such as pembrolizumab, is becoming essential in the treatment of certain cancers. Pembrolizumab works through binding of programmed cell death 1 receptor that blocks the binding of the programmed cell death ligand 1 and is commonly used in non-small cell lung cancer and...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheema, Anmol, Makadia, Bhaktidevi, Karwadia, Tejas, Bajwa, Ravneet, Hossain, Mohammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862076/
https://www.ncbi.nlm.nih.gov/pubmed/29581809
http://dx.doi.org/10.14740/wjon1085w
_version_ 1783308165029298176
author Cheema, Anmol
Makadia, Bhaktidevi
Karwadia, Tejas
Bajwa, Ravneet
Hossain, Mohammad
author_facet Cheema, Anmol
Makadia, Bhaktidevi
Karwadia, Tejas
Bajwa, Ravneet
Hossain, Mohammad
author_sort Cheema, Anmol
collection PubMed
description The utility of immunotherapy, such as pembrolizumab, is becoming essential in the treatment of certain cancers. Pembrolizumab works through binding of programmed cell death 1 receptor that blocks the binding of the programmed cell death ligand 1 and is commonly used in non-small cell lung cancer and melanoma. Pembrolizumab has been reported to be associated with multiple adverse reactions such as pneumonitis, colitis, hepatitis, hypophysitis, hyperthyroidism, hypothyroidism, nephritis, and type 1 diabetes; however, pembrolizumab causing type 1 diabetes was only reported in 0.1% of the patients in clinical trials. A review of the literature generated 1,001 unique citations of which six reported cases of autoimmune diabetes associated with pembrolizumab were selected and compared. Review of the cases showed no sexual predilection and the average age of onset was 58 years old. The majority of the patients were treated for melanoma (5/6 cases), initially presented with diabetic ketoacidosis (4/6 cases), and had at one point taken ipilimumab (4/6 cases). There was no association found between the number of treatments received and the development of diabetes. With the increasing use of pembrolizumab in cancer treatment regular blood glucose monitoring during treatment, especially in patients who had also taken ipilimumab, may prevent the onset of this life-threatening complication.
format Online
Article
Text
id pubmed-5862076
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elmer Press
record_format MEDLINE/PubMed
spelling pubmed-58620762018-03-26 Autoimmune Diabetes Associated With Pembrolizumab: A Review of Published Case Reports Cheema, Anmol Makadia, Bhaktidevi Karwadia, Tejas Bajwa, Ravneet Hossain, Mohammad World J Oncol Review The utility of immunotherapy, such as pembrolizumab, is becoming essential in the treatment of certain cancers. Pembrolizumab works through binding of programmed cell death 1 receptor that blocks the binding of the programmed cell death ligand 1 and is commonly used in non-small cell lung cancer and melanoma. Pembrolizumab has been reported to be associated with multiple adverse reactions such as pneumonitis, colitis, hepatitis, hypophysitis, hyperthyroidism, hypothyroidism, nephritis, and type 1 diabetes; however, pembrolizumab causing type 1 diabetes was only reported in 0.1% of the patients in clinical trials. A review of the literature generated 1,001 unique citations of which six reported cases of autoimmune diabetes associated with pembrolizumab were selected and compared. Review of the cases showed no sexual predilection and the average age of onset was 58 years old. The majority of the patients were treated for melanoma (5/6 cases), initially presented with diabetic ketoacidosis (4/6 cases), and had at one point taken ipilimumab (4/6 cases). There was no association found between the number of treatments received and the development of diabetes. With the increasing use of pembrolizumab in cancer treatment regular blood glucose monitoring during treatment, especially in patients who had also taken ipilimumab, may prevent the onset of this life-threatening complication. Elmer Press 2018-02 2018-03-08 /pmc/articles/PMC5862076/ /pubmed/29581809 http://dx.doi.org/10.14740/wjon1085w Text en Copyright 2018, Cheema et al. http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Cheema, Anmol
Makadia, Bhaktidevi
Karwadia, Tejas
Bajwa, Ravneet
Hossain, Mohammad
Autoimmune Diabetes Associated With Pembrolizumab: A Review of Published Case Reports
title Autoimmune Diabetes Associated With Pembrolizumab: A Review of Published Case Reports
title_full Autoimmune Diabetes Associated With Pembrolizumab: A Review of Published Case Reports
title_fullStr Autoimmune Diabetes Associated With Pembrolizumab: A Review of Published Case Reports
title_full_unstemmed Autoimmune Diabetes Associated With Pembrolizumab: A Review of Published Case Reports
title_short Autoimmune Diabetes Associated With Pembrolizumab: A Review of Published Case Reports
title_sort autoimmune diabetes associated with pembrolizumab: a review of published case reports
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862076/
https://www.ncbi.nlm.nih.gov/pubmed/29581809
http://dx.doi.org/10.14740/wjon1085w
work_keys_str_mv AT cheemaanmol autoimmunediabetesassociatedwithpembrolizumabareviewofpublishedcasereports
AT makadiabhaktidevi autoimmunediabetesassociatedwithpembrolizumabareviewofpublishedcasereports
AT karwadiatejas autoimmunediabetesassociatedwithpembrolizumabareviewofpublishedcasereports
AT bajwaravneet autoimmunediabetesassociatedwithpembrolizumabareviewofpublishedcasereports
AT hossainmohammad autoimmunediabetesassociatedwithpembrolizumabareviewofpublishedcasereports